Published in J Biol Chem on May 29, 2007
PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res (2008) 3.92
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A (2009) 3.39
The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov (2012) 3.18
Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci U S A (2008) 2.42
Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res (2008) 1.98
Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci U S A (2008) 1.86
Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem (2009) 1.65
High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res (2010) 1.56
Cholesterol, the central lipid of mammalian cells. Curr Opin Cell Biol (2010) 1.54
The PCSK9 decade. J Lipid Res (2012) 1.50
Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. Biochem J (2007) 1.48
Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation. J Biol Chem (2013) 1.29
Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J (2009) 1.24
Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice. J Lipid Res (2008) 1.18
Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS One (2013) 1.18
In vivo evidence that furin from hepatocytes inactivates PCSK9. J Biol Chem (2010) 1.18
PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1. EMBO Rep (2008) 1.17
Self-association of human PCSK9 correlates with its LDLR-degrading activity. Biochemistry (2008) 1.16
Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events. J Biol Chem (2010) 1.04
Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. PLoS One (2012) 1.04
Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids Health Dis (2011) 1.03
PCSK9 function and physiology. J Lipid Res (2008) 1.03
Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation. J Biol Chem (2012) 1.00
Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels. J Biol Chem (2012) 0.99
The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway. J Biol Chem (2012) 0.96
Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2). J Biol Chem (2013) 0.96
Molecular spectrum of autosomal dominant hypercholesterolemia in France. Hum Mutat (2010) 0.95
Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other. J Biol Chem (2015) 0.95
The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des Devel Ther (2013) 0.94
Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. J Lipid Res (2009) 0.93
PCSK9 function and physiology. J Lipid Res (2008) 0.92
PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol (2014) 0.91
Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor. J Biol Chem (2013) 0.90
Isolation and characterization of the circulating truncated form of PCSK9. J Lipid Res (2014) 0.90
Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein. J Biol Chem (2011) 0.90
FXR an emerging therapeutic target for the treatment of atherosclerosis. J Cell Mol Med (2010) 0.89
The proprotein convertase subtilisin/kexin type 9 (PCSK9) active site and cleavage sequence differentially regulate protein secretion from proteolysis. J Biol Chem (2014) 0.86
Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9). J Biol Chem (2012) 0.86
Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). Basic Res Cardiol (2015) 0.85
Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody. J Lipid Res (2015) 0.85
Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts. J Lipid Res (2013) 0.83
Evidence for positive selection in the C-terminal domain of the cholesterol metabolism gene PCSK9 based on phylogenetic analysis in 14 primate species. PLoS One (2007) 0.82
Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9. J Biomed Res (2015) 0.82
Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function. PLoS One (2015) 0.80
Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding. J Lipid Res (2013) 0.79
Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line. J Biol Chem (2015) 0.78
Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists. Nat Struct Mol Biol (2017) 0.78
Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease. Lipids Health Dis (2016) 0.77
Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain. PLoS One (2016) 0.77
PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9. Curr Opin Endocrinol Diabetes Obes (2015) 0.76
Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases. Scientifica (Cairo) (2012) 0.76
MicroRNA-497 Induces Apoptosis and Suppresses Proliferation via the Bcl-2/Bax-Caspase9-Caspase3 Pathway and Cyclin D2 Protein in HUVECs. PLoS One (2016) 0.75
A non canonical subtilase attenuates the transcriptional activation of defence responses in Arabidopsis thaliana. Elife (2016) 0.75
PCSK9 inhibitors: A new era of lipid lowering therapy. World J Cardiol (2017) 0.75
Foiling IDOL to Help Control Cholesterol. Circ Res (2016) 0.75
Point mutations at the catalytic site of PCSK9 inhibit folding, autoprocessing, and interaction with the LDL receptor. Protein Sci (2016) 0.75
The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol. Glob Cardiol Sci Pract (2017) 0.75
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
Molecular mediators of hepatic steatosis and liver injury. J Clin Invest (2004) 9.40
Human fatty liver disease: old questions and new insights. Science (2011) 8.03
Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J Biol Chem (2002) 5.89
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A (2008) 4.57
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A (2005) 4.56
Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem (2004) 3.93
Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J Clin Invest (2002) 3.85
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest (2006) 3.54
Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc Natl Acad Sci U S A (2004) 3.54
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem (2007) 3.45
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet (2006) 3.38
LXRs regulate the balance between fat storage and oxidation. Cell Metab (2005) 2.75
Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. J Clin Invest (2004) 2.66
Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci U S A (2008) 2.42
Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes (2010) 2.10
Schoenheimer effect explained--feedback regulation of cholesterol synthesis in mice mediated by Insig proteins. J Clin Invest (2005) 2.03
Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res (2008) 1.98
WholePathwayScope: a comprehensive pathway-based analysis tool for high-throughput data. BMC Bioinformatics (2006) 1.95
Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab (2009) 1.95
Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice. J Lipid Res (2008) 1.91
The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab (2012) 1.79
Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy. Cell Metab (2009) 1.79
Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature (2007) 1.66
Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem (2009) 1.65
Identification of two mammalian reductases involved in the two-carbon fatty acyl elongation cascade. J Biol Chem (2002) 1.63
Deletion of ELOVL5 leads to fatty liver through activation of SREBP-1c in mice. J Lipid Res (2008) 1.61
Cholesterol accumulation and liver cell death in mice with Niemann-Pick type C disease. Hepatology (2005) 1.48
ATP-citrate lyase deficiency in the mouse. J Biol Chem (2003) 1.35
Compensatory increase in fatty acid synthesis in adipose tissue of mice with conditional deficiency of SCAP in liver. Cell Metab (2005) 1.34
Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation. J Biol Chem (2013) 1.29
Integrated expression profiling and genome-wide analysis of ChREBP targets reveals the dual role for ChREBP in glucose-regulated gene expression. PLoS One (2011) 1.27
The Xbp1s/GalE axis links ER stress to postprandial hepatic metabolism. J Clin Invest (2012) 1.23
Induced polymerization of mammalian acetyl-CoA carboxylase by MIG12 provides a tertiary level of regulation of fatty acid synthesis. Proc Natl Acad Sci U S A (2010) 1.21
Crystal structure of Spot 14, a modulator of fatty acid synthesis. Proc Natl Acad Sci U S A (2010) 1.15
Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. J Clin Invest (2012) 1.14
Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans. J Lipid Res (2010) 1.03
Human 1-acylglycerol-3-phosphate O-acyltransferase isoforms 1 and 2: biochemical characterization and inability to rescue hepatic steatosis in Agpat2(-/-) gene lipodystrophic mice. J Biol Chem (2011) 1.01
Temporal regulation of nuclear factor one occupancy by calcineurin/NFAT governs a voltage-sensitive developmental switch in late maturing neurons. J Neurosci (2013) 0.95
Regulation of the CDP-choline pathway by sterol regulatory element binding proteins involves transcriptional and post-transcriptional mechanisms. Biochem J (2003) 0.94
Gallstone disease and its complications. Semin Gastrointest Dis (2003) 0.94
Metabolic response to high-carbohydrate and low-carbohydrate meals in a nonhuman primate model. Am J Physiol Endocrinol Metab (2012) 0.92
Enhanced fatty acid flux triggered by adiponectin overexpression. Endocrinology (2011) 0.92
Hepatic gluconeogenesis is enhanced by phosphatidic acid which remains uninhibited by insulin in lipodystrophic Agpat2-/- mice. J Biol Chem (2014) 0.88
Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts. J Lipid Res (2013) 0.83
Upregulation of hepatic LDL transport by n-3 fatty acids in LDL receptor knockout mice. J Lipid Res (2002) 0.83
Leptin ameliorates insulin resistance and hepatic steatosis in Agpat2-/- lipodystrophic mice independent of hepatocyte leptin receptors. J Lipid Res (2013) 0.83
Oxysterol activation of phosphatidylcholine synthesis involves CTP:phosphocholine cytidylyltransferase alpha translocation to the nuclear envelope. Biochem J (2009) 0.80
Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people. Transl Res (2011) 0.78
Opening up new fronts in the fight against cholesterol. Elife (2013) 0.77
Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation. Cell Metab (2017) 0.75